Healthcare ❯ Pharmaceuticals ❯ Abortion Medications

Mifepristone

Telehealth Services Misoprostol FDA Regulations Telehealth Prescriptions Telemedicine Remote Dispensing Telehealth Access Telemedicine Prescriptions Access to Medication Risk Evaluation and Mitigation Strategy Legal Challenges Safety Concerns Drug Regulation Telehealth Prescribing Mifeprex Medication Safety Claims Drug Administration Policies Access Regulations Regulatory Framework Pro-Life Issues Chemical Abortion Telehealth Health Risks Drug Safety Reviews Drug Approval Processes Distribution Regulations Access Issues Safety and Efficacy

Appeals Court Hears Louisiana Challenge to Mail Delivery of Abortion Drug

A 5th Circuit panel questioned whether Louisiana has legal standing as the FDA conducts a safety and REMS review that could determine nationwide telehealth and mail access.

Virginia Judge Orders FDA to Reconsider 2023 Abortion‑Pill Restrictions

Supreme Court Blocks 5th Circuit, Keeps Abortion Pill Mail Access for Now

Supreme Court Restores Telehealth and Mail Access to Abortion Pill for Now

Supreme Court Temporarily Restores Mail and Telehealth Access to Abortion Pill

Supreme Court Temporarily Restores Mail and Telehealth Access to Mifepristone

Appeals Court Blocks Mailed Abortion Pills, Reinstates In-Person Pickup Nationwide

Report Says Complications Rose After FDA Allowed Mail-Order Abortion Pills

Republicans Press Trump Administration to Halt Mail-Order Abortion Pills Crossing State Lines

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

Missouri AG Files Suit Over Planned Parenthood’s Mifepristone Safety Claims